<DOC>
	<DOCNO>NCT02310672</DOCNO>
	<brief_summary>The study evaluate effect macitentan right ventricular hemodynamic property patient symptomatic pulmonary arterial hypertension . Patients treat macitentan 1 year . Patients undergo right heart catheterization ( RHC ) baseline Week 26 . They also undergo cardiac magnetic resonance imaging ( MRI ) baseline , Week 26 Week 52 . Safety monitor throughout study . The study three stub-studies . Each patient participate sub-study one sub-study . The sub-studies : ( 1 ) metabolism sub-study ( PET-MR scan ) ; ( 2 ) biopsy sub-study ( biopsy take RHC ) ; ( 3 ) Echo sub-study .</brief_summary>
	<brief_title>REPAIR : Right vEntricular Remodeling Pulmonary ArterIal hypeRtension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent prior studymandated procedure 2 . Symptomatic pulmonary arterial hypertension ( PAH ) 3 . World Health Organization ( WHO ) Functional Class ( FC ) I III 4 . PAH etiology belong one follow group accord Nice classification : Idiopathic PAH Heritable PAH Drug toxininduced PAH PAH associate congenital heart disease : simple ( atrial septal defect , ventricular septal defect , patent ductus arteriosus ) congenital systemic pulmonary shunt least 2 year post surgical repair 5 . Hemodynamic diagnosis PAH confirm right heart catheterization ( RHC ) screen showing : • mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg PCWP ( pulmonary capillary wedge pressure ) leave ventricular end diastolic pressure ( LVEDP ) ≤ 12 mmHg pulmonary vascular resistance ( PVR ) ≥ 4 Wood Units ( WU ) ( 320 dyn.sec.cm5 ) 12 mmHg ≤ PCWP LVEDP ≤ 15 mmHg PVR ≥ 6WU ( 480 dyn.sec.cm5 ) 6 . 6minute walk distance ( 6MWD ) ≥ 150 screen 7 . For patient treated oral diuretic , treatment dose must stable least 1 month prior RHC screen period 8 . For patient treated phosphodiesterase type5 ( PDE5 ) inhibitor , treatment dose must stable least 3 month prior RHC screen period 9 . For patient treat beta blocker , treatment dose must stable least 1 month prior RHC screen period 10 . Men woman ≥18 &lt; 65 year 11 . Women childbearing potential ( define protocol ) must : Have negative serum pregnancy test screen negative urine pregnancy test Day 1 , Agree use reliable method contraception ( define protocol ) screen 30 day study treatment discontinuation , Agree perform monthly pregnancy test 30 day study treatment discontinuation 1 . Body weight &lt; 40 kg 2 . Body mass index ( BMI ) &gt; 35kg/m2 . For patient 30kg/m2 &lt; BMI &lt; 35kg/m2 , eligibility form submit Steering Committee member reserve right exclude patient . 3 . Pregnancy , breastfeed intention become pregnant study 4 . Recently start ( &lt; 8 week prior inform consent signature ) plan cardiopulmonary rehabilitation program 5 . Known concomitant lifethreatening disease life expectancy &lt; 12 month 6 . Any condition likely affect protocol treatment compliance 7 . Hospitalization PAH within 3 month prior inform consent signature 8 . Left atrial volume index body surface area ≥ 43mL/m2 echocardiography cardiac MRI 9 . Valvular disease grade 2 high 10 . History pulmonary embolism deep vein thrombosis 11 . Documented moderate severe chronic obstructive pulmonary disease 12 . Documented moderate severe restrictive lung disease 13 . Historical evidence significant coronary artery disease establish : History myocardial infarction More 50 % stenosis coronary artery ( percutaneous coronary intervention angiography ) Elevation ST segment electrocardiogram History coronary artery bypass graft Stable angina 14 . Diabetes mellitus 15 . Moderate severe renal insufficiency ( calculated creatinine clearance &lt; 60 mL/min/1.73 m2 ) 16 . Cancer 17 . Systolic blood pressure &lt; 90 mmHg 18 . Severe hepatic impairment ( without cirrhosis ) accord National Cancer Institute organ dysfunction work group criterion , define total bilirubin &gt; 3 × upper limit normal range ( ULN ) accompany aspartate aminotransferase ( AST ) elevation &gt; ULN Screening . 19 . Hemoglobin &lt; 100g/L 20 . AST and/or alanine aminotransferase ( ALT ) &gt; 3× ULN 21 . Need dialysis 22 . Responders acute vasoreactivity test base medical history 23 . Prior use endothelin receptor antagonist ( ERAs ) , stimulators soluble guanylate cyclase prostacyclin prostacyclin analogues 24 . Treatment strong inducer cytochrome P450 isozyme 3A4 ( CYP3A4 ) within 4 week prior study treatment initiation ( e.g. , carbamazepine , rifampicin , rifabutin , phenytoin St. John 's Wort ) 25 . Treatment strong inhibitor CYP3A4 within 4 week prior study treatment initiation ( e.g. , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , nefazodone , ritonavir , saquinavir ) 26 . Treatment another investigational drug ( plan , take within 3 month prior study treatment initiation ) . 27 . Hypersensitivity ERA excipients formulation macitentan ( lactose , magnesium stearate , microcrystalline cellulose , povidone , sodium starch glycolate , polyvinyl alcohol , polysorbate , titanium dioxide , talc , xanthan gum , lecithin soya ) 28 . Claustrophobia 29 . Permanent cardiac pacemaker , automatic internal cardioverter 30 . Metallic implant ( e.g. , defibrillator , neurostimulator , hear aid , permanent use infusion device ) 31 . Atrial fibrillation , multiple premature ventricular atrial contraction , condition would interfere proper cardiac gating MRI . 32 . For patient enrol metabolism substudy : glucose intolerance 33 . For patient enrol biopsy substudy : PAH etiology belong Nice classification 1.4.4 : PAH associate congenital heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>